<DOC>
	<DOCNO>NCT00503412</DOCNO>
	<brief_summary>Open , non-randomised , radiolabelled , single centre study total six patient solid metastatic tumor determine rate route elimination 14C-AZD2171 metabolite .</brief_summary>
	<brief_title>Phase I Orally Administered 14C-AZD2171 Patients With Solid Metastatic Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>histologically confirm metastatic tumor refractory standard therapy life expectancy 12 week longer WHO performance status 012 radiotherapy chemotherapy within 4 week start study treatment patient history poorly control hypertension history evidence medical condition might affect gastrointestinal function patient participate radiolabelled study last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>phase I</keyword>
	<keyword>AZD2171</keyword>
	<keyword>solid tumor</keyword>
	<keyword>metastatic tumor</keyword>
</DOC>